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Clinical Pharmacology of Antineoplastic
Drugs. Ed. H. M. PINEDO (1978). Elsevier/
North-Holland. 324pp. US$48.00.
This book provides a clear and concise
summary of the workshop on Methods in
Cancer Research held in Lunteren, The
Netherlands, on 24 and 25 April 1978, and is
the first of a series on Applied Methods in
Oncology.
The first part is devoted to the clinical
pharmacology ofmethotrexate, and it is good
to see that the important role of "low dose"
methotrexate has not been forgotten amidst
the current enthusiasm for "high dose"
therapy. There are concise reviews of the
current methods of measuring methotrexate
in biological fluids and attempts to relate
toxicity to clinical and kinetic parameters
are well covered. This logically leads to the
problematic area of prevention of toxicity,
and animal and human studies of thymidine
and carboxypeptidase GI rescue are pre-
sented.
The second half attempts to review, of
necessity briefly, the clinical pharmacology
of many of the common antitumour agents,
including adriamycin, bleomycin, vinca alka-
loids and c68 platinum, with reference also to
the newer derivatives of these established
agents currently undergoing evaluation.
Emphasis is again put on the measurement of
the agents and their metabolites.
Each half is concluded with a summary of
the discussion which followed the presenta-
tion of the papers. The discussion following
the papers on methotrexate provides further
useful information; that following the second
half adds little to the book.
Over the past few years we have certainly
come to appreciate the usefulness of monitor-
ing serum levels of methotrexate, and to
enable the safe use of all cytotoxics, know-
ledge of their pharmacokinetic properties is
now an established requirement. This volume
will certainly provide good reading material
for those wishing to keep in touch with the
clinical pharmacology of antineoplastic
agents.
A. STEWART
IARC Monographs on the Evaluation of
the Carcinogenic Risk of Chemicals to
Humans, Vol. 17: Some N-Nitroso
Compounds (1978). Lyon: International
Agency for Research in Cancer. 365 pp.
Sw.fr.50. (Distributed for the IARC by
WHO.)
This addition to the established IARC
series brings together data on 17 N-nitroso
compounds and some of their derivatives. In
the preamble to this volume the guiding
criteria for the evaluation ofcarcinogenic risk
to humans are stated, and the importance of
quantitative data is emphasized.
The monographs themselves cover data
(which in the case of biological studies are
extensive and well documented) on: physical
and chemical properties; industrial produc-
tion and uses; occurrence and analysis;
carcinogenicity, embryogenicity and terato-
genicity in animals: mutagenicity and short-
term screening tests; toxicity and metabo-
lism. Each monograph ends with an assess-
ment of the likely human exposure and an
evaluation of the carcinogenic risk presented
to humans. Of the 17 compounds examined,
it is concluded that 13 contribute to low-level
exposure of the general population. While no
epidemiological or other direct evidence exists
to link N-nitroso compounds with cancer
incidence in man, the IARC working group
considers that for 15 compounds there is
sufficient evidence of carcinogenicity in
animals, and recommends that they should
be regarded as carcinogenic in man.
This book contains a wealth ofdiverse data
and should prove useful to workers in the
fields ofnitrosamine carcinogenesis and cancer
epidemiology.
S. A. KRYTOPOULOS
IARC Monographs on the Evaluation of
the Carcinogenic Risk of Chemicals
to Humans, Vol. 18: Polychlorinated
Biophenyls and Polybrominated Bi-
phenyls (1978). Lyon: International
Agency for Research on Cancer. 140 pp.
Sw.fr.20. (Distributed for IARC by WHO.)